S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin
Open Access
- 18 November 2019
- journal article
- research article
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 12 (1) , 1-11
Abstract
Background: Ovarian cancer is the leading cause of gynecological cancer-related mortality. The novel oncogene S100A10 has been reported to be involved in cancer cell proliferation, invasion and metastasis. The role of S100A10 in ovarian cancer has not been well studied and the effect of S100A10 on chemotherapy remains unclear. The aims of the present study were to investigate the functional role of S100A10 in the progression and carboplatin sensitivity of ovarian cancer. Methods: We examined the expression levels in tissues of S100A10 in 138 cases of ovarian cancer by IHC. To determine the functional roles of downregulated S100A10 in ovarian cancer, cell proliferation, colony formation, cell migration and invasion assays were performed. Chemoresistance was analyzed by apoptosis assay. A xenograft tumor model was established to confirm the role of S100A10 in carboplatin resistance in vivo. Using Western blot assays, we also explored the possible mechanisms of S100A10 in ovarian cancer. Results: The results showed that increased expression of S100A10 was positively associated with carboplatin resistance (P < 0.001), tumor grade (P = 0.048) and a poorer prognosis (P = 0.0053). Functional analyses demonstrated that S100A10 suppression significantly suppressed ovarian cancer cell proliferation, colony formation, cell migration and invasion, remarkably increased carboplatin-induced apoptosis in SKOV3 and A2780 cells and inhibited tumor growth in vivo. Downregulation of S100A10 expression could inhibit cell proliferation and enhance ovarian cancer cell sensitivity to carboplatin, possibly involving the regulation of cleaved-Caspase3 and cleaved-PARP. Conclusions: Together, the results of the present study reveal that S100A10 expression can be used as a predictive marker for the prognosis of ovarian cancer and chemosensitivity to carboplatin.Keywords
Funding Information
- National Natural Science Foundation of China (81650015, 81130043, 81472452)
- CAMS Initiative for Innovative Medicine (2017-I2M-3-004)
This publication has 34 references indexed in Scilit:
- MiR-590-5P Inhibits Growth of HepG2 Cells via Decrease of S100A10 Expression and Inhibition of the Wnt PathwayInternational Journal of Molecular Sciences, 2013
- The Annexin A2/S100A10 System in Health and Disease: Emerging ParadigmsJournal of Biomedicine and Biotechnology, 2012
- S100 proteins in cartilage: Role in arthritisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- S100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cellsProteome Science, 2011
- Plasminogen Receptor S100A10 Is Essential for the Migration of Tumor-Promoting Macrophages into Tumor SitesCancer Research, 2011
- DLC1 Interaction with S100A10 Mediates Inhibition of In Vitro Cell Invasion and Tumorigenicity of Lung Cancer Cells through a RhoGAP-Independent MechanismCancer Research, 2011
- Calprotectin, Calgranulin C, and Other Members of the S100 Protein Family in Inflammatory Bowel DiseaseDigestive Diseases and Sciences, 2011
- BRCA1-Associated Epigenetic Regulation of p73 Mediates an Effector Pathway for Chemosensitivity in Ovarian CarcinomaCancer Research, 2010
- S100A10 regulates plasminogen-dependent macrophage invasionBlood, 2010
- S100A1 Expression in Ovarian and Endometrial Endometrioid Carcinomas Is a Prognostic Indicator of Relapse-Free SurvivalAmerican Journal of Clinical Pathology, 2009